Mabylon AG, a Zurich-based biotech company developing human-derived, multi-specific antibodies for allergies, inflammation, and neurology, has raised CHF 30 million (approx. €32M) in a mix of equity and convertible loans from existing private investors. Major contributions came from former Roche management and board members.
The funding will advance Mabylon’s lead candidate, MY006 — a tri-specific antibody designed to neutralise peanut allergens — through a Phase Ia/b trial by 2027. Peanut allergy remains a high unmet medical need, with limited preventive treatment options.
Expanding a multi-allergen pipeline
Beyond MY006, the investment will accelerate:
- MY010: a multi-specific antibody targeting birch Bet v 1 and related tree, fruit, and nut allergens
- MY011: an antibody treatment for grass pollen allergies
The Startup’s antibodies are sourced from allergic patients, providing a natural match to allergen structures and potentially improving efficacy over animal model–derived antibodies.
“This financing validates our human-derived, multi-specific antibody approach and positions us to reach clinical proof-of-concept for peanut allergy while advancing our early-stage pipeline,” said Alcide Barberis, CEO of Mabylon.
Advertisement
Strengthening leadership
The company appointed Dr. Thomas Hecht to its board, succeeding Prof. Adriano Aguzzi. Hecht brings decades of biotech industry experience to support Mabylon’s clinical and commercial strategy.
“MY006 addresses a market with high unmet need. This funding enables us to progress toward proof-of-concept while expanding our portfolio,” added Gottlieb Keller, Chairman of Mabylon.
Founded to rapidly generate high-quality antibody libraries against validated targets, Mabylon leverages diverse immune repertoires from patients with relevant conditions. The company’s platform is designed to deliver best-in-class allergen-neutralising therapeutics for global markets.
